Palisade Bio Inc’s filing revealed that its CEO, CFO, Director Finley John David acquired Company’s shares for reported $4692.0 on Feb 06 ’24. In the deal valued at $0.47 per share,10,000 shares were bought. As a result of this transaction, Finley John David now holds 84,649 shares worth roughly $0.5 million.
Then, Williams Donald Allen bought 10,000 shares, generating $6,050 in total proceeds. Upon buying the shares at $0.60, the Director now owns 30,000 shares.
Before that, Finley John David bought 10,000 shares. Palisade Bio Inc shares valued at $5,590 were divested by the CEO, CFO, Director at a price of $0.56 per share. As a result of the transaction, Finley John David now holds 74,649 shares, worth roughly $0.44 million.
Price Performance Review of PALI
On Tuesday, Palisade Bio Inc [NASDAQ:PALI] saw its stock jump 42.55% to $5.93. Over the last five days, the stock has gained 9.41%. Palisade Bio Inc shares have fallen nearly -32.99% since the year began. Nevertheless, the stocks have fallen -79.19% over the past one year. While a 52-week high of $36.60 was reached on 01/29/24, a 52-week low of $3.82 was recorded on 04/12/24. SMA at 50 days reached $5.90, while 200 days put it at $11.10. A total of 28.93 million shares were traded, compared to the trading of 0.11 million shares in the previous session.
Levels Of Support And Resistance For PALI Stock
The 24-hour chart illustrates a support level at 4.30, which if violated will result in even more drops to 2.66. On the upside, there is a resistance level at 8.61. A further resistance level may holdings at 11.28. The Relative Strength Index (RSI) on the 14-day chart is 54.30, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.60, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 63.81%. Stochastics %K at 18.23% indicates the stock is a buying.
